Michele Korfin has served as our Chief Commercial Officer since October 2018 and assumed the role of Chief Operating Officer in March 2019. Ms. Korfin has over 20 years of experience in oncology, focused on product launches, oncology marketing strategy, commercial sales, market access and government affairs. From 2016 to July 2018, Ms. Korfin was Vice President of Market Access at Kite Pharma, where she oversaw the market access strategy for Yescarta®, the first approved CAR-T therapy in lymphoma. Prior to joining Kite, Ms. Korfin spent over a decade at Celgene in key strategic and operational roles, including head of oncology sales and overseeing the global development programs for REVLIMID® in lymphoma and CLL. She led Celgene’s oncology sales force of over 120 representatives generating $650M in revenue for ABRAXANE®, now a standard of care in pancreatic cancer. Ms. Korfin earned an MBA from Harvard and a B.S. in Pharmacy from Rutgers. Michele is a Board of Trustees of BioNJ.